🔗 Share this article

As America undertakes unprecedented revisions to its vaccination recommendations, a particular individual appears in a surprising turn: Dr. Tracy Beth Høeg, a Danish American sports physician and public health researcher who rose to prominence by expressing skepticism about Covid vaccines during the pandemic and has concentrated on possible fatalities following COVID-19 vaccination in her short position at the FDA.

Scheduled Changes to Pediatric Immunization Program

Health officials had intended to unveil radical changes to the childhood immunization program recently, aligning the US with the Danish vaccine program, it is understood – a significant shift that would put the US out of alignment with many the world with insufficient data for public health gain. The announcement has been delayed until the next year.

Instead of Vinay Prasad, Høeg is listed to speak at the event. She was newly appointed interim head of the FDA’s CDER, the fifth appointee to run the center this calendar year.

Consolidating Power at the Regulatory Body

Høeg's temporary position could signify a tighter collaboration between the drug and biologics divisions as Høeg and Dr. Prasad solidify control at the agency – and it suggests a renewed priority upon rolling back already-approved vaccines at the FDA.

Dr. Høeg has often pushed for discontinuing specific childhood vaccine recommendations in the US so as to align more in line with the Danish model, a society with comprehensive healthcare and a citizenry roughly the population of Wisconsin’s.

To date statements, she has continued to focus on vaccines – typically the domain of Dr. Prasad, head of the FDA’s CBER – rather than drug regulation.

Questions Over Qualifications

Dr. Høeg has no apparent background in pharmaceutical research, regulation or management, which has been typical for former heads of the biologics center. She has been employed at the FDA as a key advisor to the commissioner and the vaccine center since March.

“She appears not to have the requisite experience” for running the pharmaceutical oversight division, said a neurologist and psychiatrist. “She lacks experience running a randomized controlled trial. She lacks experience in leading a sizeable institution. She lacks background in industry regulation.”

Past commissioners of the center would “be deeply familiar with legal statutes and the science of drug development”, said Janet Woodcock. “Clearly, she has not acquired the type of experience that prior appointees who led CBER have had.”

The drug center has an enormous workload at the agency, the former commissioner emphasized.

“Everybody just zeroes in on the new drug program, but the off-patent medication office authorizes a multitude of off-brand pharmaceuticals. There is also a biosimilars program, non-prescription drug unit and other areas, and every single one need to be managed,” she said. “The thing you overlook, that’s the thing that I always told people is going to cause problems.”

Additionally, a significant administrative component to the position, which supervises more than 5,000 personnel. “It is a massive leadership role, if you do it right,” the former official said.

Response and Controversial Initiatives

In response to questions about Dr. Høeg's credentials and whether this selection represents increased cooperation among agency officials on immunizations, a spokesperson responded that the “inquiries rely on flawed assumptions”.

“Her resume matches the functions of her position,” the spokesperson explained, noting the time Dr. Høeg spent counseling the FDA commissioner on “medication safety and oversight research, including computational safety modeling and immunization monitoring”.

As the temporary head, Dr. Høeg assumes responsibility for the agency head's new expedited review system, a disputed one-day medication authorization process that reportedly troubled her former heads. “How are these medications being chosen for this fast-track system? Who is making the calls?” Dr. Howard questioned. “There is a lot of confidentiality occurring at the regulatory body right now.”

Broadly speaking, he said, “the Food and Drug Administration seems to be moving towards more relaxed oversight of all drugs, except for vaccines.”

Documented History on Vaccines

With immunizations, Høeg has a clearer, if problematic, past, Howard observe. She published a analysis using non-validated volunteer-provided data to assess the rate of heart inflammation following COVID-19 vaccination. She consulted for the Florida chief medical officer Dr. Joseph Ladapo, who allegedly have modified findings to imply COVID-19 vaccines are riskier than they are.

Among her “policy goals” for the incoming government featured altering rules for recently developed shots and halting “optional” immunizations, she stated post-election on a podcast. At the FDA, Høeg has allegedly floated the idea of excluding teenage boys from obtaining Covid vaccinations.

“She is an all-around ideologue who begins with her beliefs and works backwards to retrofit the science in a very disingenuous, dishonest fashion,” Dr. Howard said.

Taking Control and a “Revenge Tour”

Høeg aligned with other dissenters, {like|